同济医学院海外校友风采——龚红

姓名/职位/现工作单位：

Dr. Hong Zebger-Gong, MD (龚红）

Medical Director

PAREXEL International

Berlin, Germany

同济医学院求学与工作经历：

1985-1990 医学本科 (二大班)

1990-1996 助教和硕士研究生 (寄生虫学)

联系方式：

Dr. Hong Zebger-Gong

Medical Services

PAREXEL International

Am Bahnhof Westend 11

14059 Berlin, Germany

Email：hong_gong@web.de

校友简介:

Dr. Hong Zebger-Gong received her Doctor of Medicine in Oncology from University of Essen Medical School, Germany. She did her postdoctoral fellowships at Tufts University School of Medicine, Boston, and in Charité University Hospital, Berlin where she also acted as Group Leader. She was Assistant Professor at University of Aarhus, Denmark. She worked for two startup pharmaceutical companies in California and Denmark responsible for drug development in oncology and nephrology. As Medical Director with PAREXEL International since 2009 Dr. Zebger-Gong serves as internal expert in Oncology/Hematology Working Groups and as Global Medical Monitor on multiple global trials mainly in oncology studies with successful oncology trial experiences that brought the approvals of new drugs by FDA, EMA and other regulatory agencies. Her product expertise through preclinical to clinical trials Phase I-IV are anticancer drugs with emphasis on tumor angiogenesis, immuno-oncology and other targeted therapies. She has publications in peer-reviewed journals including coauthor with Nobel Prize winner and held oral/poster presentations at international conferences.

龚红博士毕业于华中科大同济医学院,获得德国Essen埃森大学肿瘤学医学博士学位。曾在波士顿Tufts塔夫茨大学医学院做博士后和柏林Charité夏洛蒂大学医学院做博士后兼任研究组长。龚红博士曾任职丹麦Aarhus(奥胡斯)大学助理教授, 曾在加利福尼亚和丹麦的两家创业制药公司负责肿瘤学和肾脏病学的药物开发。自2009年以来龚红博士担任PAREXEL鼎晖的Medical Director医疗总监负责参与肿瘤药物的全球性临床试验，其中多个药物成功通过了FDA、EMA等监管机构的批准。龚红博士在肿瘤学临床前试验和临床试验1期至4期方面有丰富经验，主要专注于肿瘤血管生成，肿瘤免疫和其他靶向治疗。龚红博士在核心学术期刊上出版了多篇文章包括与诺贝尔奖得主合著的文章，并多次在国际会议上发言。